Heart Failure Is Not a Heart Attack: Symptoms, Stages, and How It Is Managed

Heart failure is one of the most misunderstood diagnoses in medicine, in large part because the name itself is misleading. Heart failure does not mean the heart has stopped or is about to stop. It means the heart muscle is not pumping efficiently enough to meet the body's circulatory demands, or that it cannot fill adequately between beats. Approximately 6.7 million Americans over the age of 20 are currently living with heart failure, and around 960,000 new cases are diagnosed each year. Despite significant advances in treatment over the past two decades, it remains a serious, progressive condition — but one that modern medicine can meaningfully slow, and in some patients partially reverse.

What Heart Failure Actually Is

The heart has two primary mechanical jobs: squeezing blood out during systole (the contraction phase) and filling with blood during diastole (the relaxation phase). Heart failure arises when either of these functions is impaired. This distinction is clinically important because the two forms of heart failure have different causes, different diagnostic profiles, and partially different treatments.

HFrEF: Heart Failure With Reduced Ejection Fraction

HFrEF, historically called systolic heart failure, is characterized by a weakened, dilated heart that cannot contract forcefully enough to eject an adequate volume of blood. Ejection fraction (EF) — the percentage of blood pumped out of the left ventricle with each beat — is the key measurement. A normal EF is 55 to 70 percent. In HFrEF, the EF is 40 percent or below. Common causes include prior heart attack (which damages heart muscle tissue), long-standing uncontrolled hypertension, viral myocarditis, alcohol-related cardiomyopathy, and inherited cardiomyopathies. HFrEF accounts for roughly half of all heart failure cases and has the most robust evidence base for pharmacological treatment.

HFpEF: Heart Failure With Preserved Ejection Fraction

HFpEF, historically called diastolic heart failure, is characterized by a stiff, thickened heart that squeezes normally (EF ≥ 50%) but cannot relax adequately between beats, limiting how much blood can enter. The underlying driver is usually chronic hypertension, obesity, diabetes, or aging itself — all of which cause the heart muscle to stiffen over time. HFpEF has historically been more difficult to treat pharmacologically, though SGLT2 inhibitors have recently demonstrated mortality benefit in this population as well. It is more common in older women and in patients with metabolic syndrome.

HFmrEF

A third category, HFmrEF (mildly reduced ejection fraction, EF 41–49%), is increasingly recognized as a distinct phenotype with its own clinical course. It often responds to the same therapies used for HFrEF.

Recognizing the Symptoms

Heart failure symptoms arise because the failing heart creates a backup of pressure in the pulmonary or systemic circulation, or because cardiac output is simply insufficient to supply adequate oxygen to tissues. The symptoms are often subtle at first and can be confused with deconditioning or aging.

Dyspnea (Shortness of Breath)

Dyspnea on exertion is typically the first symptom patients notice. As heart failure progresses, the threshold for breathlessness drops — from exertion to minimal activity to rest. The mechanism is pulmonary congestion: fluid backs up into the lungs because the failing left ventricle cannot keep pace with venous return. Patients often describe the feeling as an inability to take a full breath or a sense of air hunger.

Orthopnea and Paroxysmal Nocturnal Dyspnea

Orthopnea is the inability to lie flat without becoming short of breath, which is why heart failure patients often sleep propped up on multiple pillows. When a person lies down, fluid redistributes from the legs to the lungs. Paroxysmal nocturnal dyspnea (PND) is a related phenomenon in which patients wake suddenly from sleep, severely short of breath, often feeling the need to sit upright or stand at a window. Both are highly specific symptoms of heart failure rather than lung disease.

Peripheral Edema

Swelling of the legs, ankles, and feet — often worse by evening and improved overnight — reflects venous congestion and sodium retention. In more advanced cases, fluid accumulates in the abdomen (ascites) and around the lungs (pleural effusions). Patients may also notice rapid weight gain of two to five pounds over several days, which often heralds a decompensation episode before other symptoms worsen.

Fatigue and Exercise Intolerance

Chronic low cardiac output leads to skeletal muscle underperfusion and altered metabolism, producing profound fatigue disproportionate to activity. Patients describe feeling exhausted after activities they previously performed without difficulty — climbing stairs, carrying groceries, or even showering.

Other Symptoms

Persistent cough or wheeze (cardiac asthma), reduced urine output, confusion or cognitive slowing in severe cases, and loss of appetite due to gut congestion are all recognized features of advancing heart failure.

NYHA Functional Classification

The New York Heart Association (NYHA) classification system grades heart failure severity according to functional limitation:

• Class I: No limitation. Ordinary physical activity does not cause symptoms.
• Class II: Slight limitation. Comfortable at rest; ordinary activity causes dyspnea, fatigue, or palpitations.
• Class III: Marked limitation. Comfortable at rest; less-than-ordinary activity causes symptoms.
• Class IV: Symptoms at rest. Any physical activity increases discomfort.

Separately, the ACC/AHA staging system (Stages A through D) classifies heart failure from risk factors alone (Stage A) through refractory end-stage disease (Stage D). These two frameworks serve different purposes: NYHA grades current functional status; ACC/AHA tracks disease progression over time.

Key Diagnostic Tests

BNP and NT-proBNP

Brain natriuretic peptide (BNP) and its precursor NT-proBNP are neurohormones released by the ventricles in response to increased wall stress — essentially, the heart signaling that it is under strain. A BNP above 100 pg/mL strongly suggests heart failure in a patient with dyspnea, while a level below 35 pg/mL makes heart failure unlikely. NT-proBNP thresholds are higher (above 125 pg/mL in those under 75). These biomarkers are invaluable both for initial diagnosis and for monitoring response to treatment — a falling BNP over time suggests improving cardiac function.

Echocardiogram

The transthoracic echocardiogram (echo) is the cornerstone of heart failure diagnosis. It measures ejection fraction, assesses wall motion, evaluates valvular function, estimates filling pressures, and identifies structural abnormalities. Every patient with newly diagnosed heart failure should have an echocardiogram.

Other Tests

An ECG may reveal prior infarction, left bundle branch block, or arrhythmia. Chest X-ray can show pulmonary vascular congestion, cardiomegaly, or pleural effusions. Labs including complete metabolic panel, CBC, thyroid function, and iron studies help identify reversible causes and guide medication dosing.

GDMT: Guideline-Directed Medical Therapy

For HFrEF specifically, four pillars of medical therapy — collectively termed GDMT — have been shown in large randomized trials to reduce mortality and hospitalizations. These are not optional enhancements; they are the standard of care:

ACE Inhibitors or ARBs (or ARNI)

Renin-angiotensin system blockers reduce afterload on the heart and counteract harmful neurohormonal activation. Angiotensin-converting enzyme (ACE) inhibitors (lisinopril, enalapril) or angiotensin receptor blockers (losartan, valsartan) are foundational. Sacubitril/valsartan (Entresto), an angiotensin receptor-neprilysin inhibitor (ARNI), has superseded ACE inhibitors in many patients with HFrEF after demonstrating superior mortality reduction in the PARADIGM-HF trial, reducing cardiovascular death and heart failure hospitalization by 20 percent compared to enalapril.

Beta-Blockers

Three beta-blockers — carvedilol, metoprolol succinate, and bisoprolol — have proven mortality benefit in HFrEF. They counteract the sympathetic overdrive that characterizes failing hearts, reducing heart rate, myocardial oxygen demand, and ventricular remodeling. Beta-blockers must be started at very low doses and titrated slowly; initiating them during acute decompensation can worsen hemodynamics.

Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone and eplerenone block aldosterone, which contributes to sodium retention and cardiac fibrosis in heart failure. The RALES trial showed a 30 percent reduction in mortality with spironolactone in severe HFrEF. MRAs require monitoring of potassium and renal function, as hyperkalemia is a significant risk, particularly when combined with ACE inhibitors.

SGLT2 Inhibitors

Originally developed for type 2 diabetes, sodium-glucose cotransporter-2 inhibitors (dapagliflozin, empagliflozin) have emerged as transformative heart failure drugs. The DAPA-HF and EMPEROR-Reduced trials demonstrated that these agents reduce cardiovascular death and heart failure hospitalization by approximately 25 percent in HFrEF patients, including those without diabetes. Empagliflozin (EMPEROR-Preserved) also showed benefit in HFpEF, making it the first drug proven to reduce hospitalization in that population. Their mechanism of action in heart failure appears to involve osmotic diuresis, improved cardiac energetics, and renal protection.

Additional Therapies

Loop diuretics (furosemide, torsemide) relieve congestion but have not been shown to reduce mortality and must be used judiciously to avoid over-diuresis and worsening renal function. Hydralazine-nitrate combination is an alternative vasodilator strategy for patients who cannot tolerate ACE inhibitors or ARBs, with particular evidence in self-identified Black patients. Ivabradine reduces heart rate through a different mechanism than beta-blockers and benefits patients with persistent elevated resting heart rate despite maximized beta-blockade.

Device therapy plays a major role in advanced HFrEF. Implantable cardioverter-defibrillators (ICDs) prevent sudden cardiac death in patients with EF ≤ 35%. Cardiac resynchronization therapy (CRT) improves symptoms and survival in patients with EF ≤ 35% and wide QRS complex, by coordinating the timing of ventricular contraction. Left ventricular assist devices (LVADs) serve as bridge to transplant or destination therapy in end-stage disease.

Lifestyle Management

Fluid restriction (typically 1.5 to 2 liters daily in congested patients) and sodium restriction (less than 2 grams per day) are standard recommendations to minimize fluid retention. Daily morning weights are a practical early warning system — a gain of more than two to three pounds in 24 hours signals fluid accumulation and warrants medication adjustment or urgent contact with a clinician. Structured exercise through cardiac rehabilitation has Level IA evidence for improving functional capacity and quality of life. Alcohol should be eliminated or strictly limited, as it is directly cardiotoxic. Smoking cessation is mandatory.

Prognosis and Hospitalizations

Heart failure carries a substantial mortality burden: approximately 50 percent of patients die within five years of diagnosis in older data, though contemporary GDMT has significantly improved survival. Prognosis depends heavily on ejection fraction, NYHA class, BNP trajectory, renal function, and whether patients can tolerate and adhere to GDMT. Hospitalization for acute decompensated heart failure is itself a major prognostic event — 30-day readmission rates remain around 20 to 25 percent, and each hospitalization is associated with accelerated disease progression. Proactive monitoring, close follow-up, and prompt outpatient management of early decompensation signs are essential to keeping patients out of the hospital.

When to See a Doctor

If you experience progressive shortness of breath with exertion, swelling in your legs or ankles, waking at night unable to breathe, unexplained fatigue, or rapid weight gain of more than two to three pounds in two days, these warrant prompt cardiac evaluation. Heart failure is far more manageable when caught and treated before acute decompensation. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

What is the difference between a heart attack and heart failure?

A heart attack (myocardial infarction) is an acute event in which a blocked coronary artery cuts off blood supply to heart muscle, causing tissue death. Heart failure is a chronic syndrome in which the heart cannot pump or fill adequately, often developing gradually over years. A heart attack is a common cause of heart failure — the scar tissue left by damaged muscle weakens pump function — but heart failure has many other causes and can exist without any prior heart attack.

Can the heart recover from heart failure?

In some cases, yes. HFrEF caused by a reversible condition — alcohol cardiomyopathy, viral myocarditis, poorly controlled hypertension, or tachycardia-induced cardiomyopathy — can partially or fully recover with appropriate treatment. GDMT itself can improve ejection fraction over time in a meaningful subset of patients, a process called reverse remodeling. Complete normalization of EF occurs in roughly 40 percent of newly diagnosed HFrEF patients who achieve full GDMT at maximum tolerated doses.

What does ejection fraction of 35% mean?

An ejection fraction of 35 percent means the left ventricle is ejecting only 35 percent of its blood volume with each contraction, compared to a normal range of 55 to 70 percent. This qualifies as severely reduced and meets the threshold for device therapy consideration (ICD, and possibly CRT). It also indicates the patient should be on all four pillars of GDMT unless specific contraindications exist.

Is heart failure the same as congestive heart failure?

Congestive heart failure (CHF) is an older term that refers specifically to the congestive symptoms — fluid backup in the lungs and body — that accompany heart failure. Modern terminology simply uses "heart failure" because not all patients have congestion at all times, and the older label is considered imprecise. The two terms are used interchangeably in common conversation, but cardiologists prefer the current classification by ejection fraction subtype.

Can I exercise with heart failure?

Yes, and you should. Structured exercise through cardiac rehabilitation is among the most evidence-supported interventions for improving quality of life, functional capacity, and symptom burden in stable heart failure. The key is structured, graduated exercise guided by a cardiac rehabilitation team rather than unrestricted exertion. Patients with decompensated heart failure or acute symptoms should not exercise until stabilized.